Waxman investigates marketing practices
US Representative Henry Waxman (Democrat, California) revealed that he has sent letters to three pharmaceutical companies and two medical device makers requesting information about their marketing. The drugmakers were Eli Lilly regarding its Zyprexa (olanzapine) and AstraZeneca over Seroquel (quetiapine) - both antipsychotic drugs - and Cephalon over its narcotic fentanyl products Actiq and Fentora. The device firms were Boston Scientific and Cordis, a Johnson & Johnson subsidary, relating to their drug-eluting stents.
Rep Waxman, Chairman of the House Committee on Oversight and Government Reform, sent the letters as part of the Committee's ongoing oversight over the research and marketing practices of the pharmaceutical and medical device industries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze